INTRODUCTION
Radiotherapy for cancer has long been valued for its ability to target specific lesions to achieve tumor regression and improve patient symptoms. Though the effect of radiotherapy is typically limited to its targeted fields, reports have described response in distant tumors a phenomenon termed the abscopal effect. 1 Prior studies have demonstrated that this effect may be mediated by an enhanced immune response against tumors, 2 possibly elicited by tumorspecific antigens released by cancer cells exposed to radiation. 3 Interest in leveraging the abscopal effect has been revived by recent advances in immunotherapy. 4 Inhibitors of immune checkpoints, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1), and programmed death ligand 1 (PD-L1), have been shown to induce a strong clinical response in multiple cancer types. [5] [6] [7] [8] Also, the US Food and Drug Administration has approved PD-1 inhibitors for use against any solid tumors that have deficiencies in DNA mismatch repair (MMR). 9 These treatments block signaling pathways that normally suppress the immune system and thus can unleash a potent antitumor immune response. 8 It has been hypothesized that immunotherapies, given their immune-based mechanisms, might synergize with radiotherapy and induce a more consistent and intense abscopal effect.
In one early report, a patient with metastatic melanoma was treated with ipilimumab, a CTLA-4 inhibitor, and treatment resulted in significant regression in multiple areas of cancer after radiation was administered to a paraspinal mass. 10 The patient had temporally associated increases in activated CD4
+ T cells and antibodies against cancer antigens, which supports an immunologic basis for this effect. Similar results have been observed in non-small-cell lung cancer 11 and in small cohorts of patients with melanoma. 12, 13 Despite these promising reports, abscopal effects remain rarely discussed in the literature.
CASE REPORT
A 61-year-old woman initially presented with vaginal bleeding, and a computed tomography (CT) scan of the abdomen and pelvis showed a uterine mass with para-aortic lymphadenopathy. She underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Pathology demonstrated grade 1 endometrial adenocarcinoma with myometrial invasion and abnormal peritoneal washings, consistent with stage IIIC2 disease per the International Federation of Gynecology and Obstetrics staging system. Of note, immunohistochemical studies showed absent expression of the MMR proteins MLH1 and PMS2 (Fig 1) .
The patient was given adjuvant paclitaxel 175 mg/m 2 and an area under the curve-based carboplatin target dose of 5 for six cycles, but a subsequent CT scan revealed progression of disease. She was then sequentially treated with multiple chemotherapy agents. She received six cycles of doxorubicin (reduced to 50 mg/m 2 per cycle for severe neutropenia), but the follow-up CT scan showed enlarged pelvic lymph nodes. 3.25 mg/m 2 weekly. However, because cancer antigen-125 levels increased after two cycles, she received oral melphalan, although she again experienced disease progression. At this time, immunotherapy was considered because of data to suggest its efficacy in MMR-deficient tumors. 14 Meanwhile, the patient's performance status deteriorated rapidly, and she was no longer able to ambulate without assistance, in part because cutaneous metastases presented as large fungating masses on her left thigh. Ultimately, she started nivolumab 3 mg/kg every 2 weeks; the first cycle occurred 23 months after surgery.
Two months after nivolumab treatment initiation, a CT scan demonstrated a mixed response, with improved pulmonary metastatic disease but increased pelvic lymph nodes and a nodule of the sigmoid mesentery. Because of worsening leg pain, the patient was referred to a radiation oncologist and received palliative radiation to her left thigh, which consisted of 25 Gy in five fractions via en face photon beams. Her pain improved within 2 months, and she experienced clinical resolution of the thigh nodules. Notably, she also experienced decreased size of hepatic masses, sigmoid nodule, and retroperitoneal and pelvic lymphadenopathy.
CT obtained 2 months afterward concerningly showed progression of the sigmoid nodule and pelvic lymphadenopathy as well as marked growth of a splenic lesion and a 7-cm L3 vertebral metastasis that was causing significant back pain. The patient was again referred for palliative radiotherapy and received 20 Gy to the lumbar spine in five fractions using conventional anterior-posterior/posterior-anterior (APPA) technique. Follow-up imaging demonstrated reduction not only in the vertebral mass but also in nonirradiated areas, including the spleen, mesentery, and pelvic nodes. Clinically, the patient's back pain significantly improved; with the aid of physical therapy, she was able to ambulate independently again. However, the patient developed recurrent difficulties with walking, and progression of a nodal mass in the left external iliac chain was discovered. As a result, she received 20 Gy of radiation via APPA technique to the region. A repeat CT scan showed reduction in this mass as well as response in the hepatic and splenic masses to near resolution.
By this time, it was noted that the patient had exhibited a presumed abscopal effect after each of her radiation treatments (Fig 2) . Thus, when disease progression that included a 1.9-cm bladder mass was discovered, the possibility of using radiotherapy to induce a systemic response was considered. A plan to re-irradiate the left external iliac region was discussed extensively; ultimately, the patient underwent 25 Gy of radiation to this area. Because of significant suprapubic pain, she also received 25 Gy via modulated arc radiotherapy to the bladder mass. Two months after these treatments, radiographic response was noted in the liver and splenic lesions as well as in several pelvic nodal masses. The patient did develop hematuria and dysuria consistent with radiation-induced grade 2 cystitis, but she otherwise continues to tolerate nivolumab without high-grade toxicities.
DISCUSSION
We describe here the case of a patient with widely metastatic endometrial cancer who exhibited abscopal responses after multiple rounds of palliative radiotherapy while on nivolumab. This represents, to our knowledge, the first reported case of disease regression achieved with repeated instances of an abscopal effect. This patient experienced disease response to five separate radiotherapy treatments with concurrent PD-1 blockade, which yielded an ongoing survival benefit that lasted longer than 28 months as of this writing.
Abscopal effects are difficult to clearly identify, because multiple factors affect patient response. For example, tumor shrinkage after the first radiotherapy treatment may have represented a delayed effect of nivolumab, which can cause pseudoprogression before a definite clinical response. 15 The repeated benefit with radiotherapy in this case, however, suggests the presence of a true abscopal effect. This pattern is best illustrated with the fourth and fifth treatments, when the patient exhibited disease progression that was halted and reversed with additional radiation. Conversely, the patient's clinical improvement may have been driven by radiotherapy alone rather than by synergism with immunotherapy. Though this possibility cannot be definitively excluded, we find it unlikely that the dramatic clinical response was elicited without a contributing effect of nivolumab, especially because the MMR-deficient status implies susceptibility to PD-1 inhibition.
ascopubs.org/journal/po JCO™ Precision Oncology 3 The patient tolerated radiotherapy well, with radiation cystitis noted as the only major toxicity, but other patients may not have the same experience. Indeed, a primary limitation to multiple courses of radiotherapy has been the potential toxicities, which could be amplified by immunotherapy. However, one clinical trial showed that the use of ipilimumab with pelvic radiotherapy for prostate cancer did not result in a greaterthan-expected increase in toxicities. 16 A retrospective analysis of 133 patients with various cancer types who received both immunotherapy and radiotherapy similarly did not uncover an increase in major adverse effects. 17 Thoughtful and judicious use of these treatments, even in a repeated fashion, may be tolerated by many patients.
Not all patients treated with radiotherapy exhibit an abscopal effect, and such an effect may be dependent on patient-specific immune parameters. For example, this patient's primary tumor exhibited MMR deficiency, which is a possible sensitizing factor to radiotherapy, 18 presumably because the ability of cancer cells to repair DNA damage inflicted by radiation is reduced. 19 In addition, MMR deficiency has been associated with an increase in tumor mutations and tumor-specific neoantigens. 9 This attribute may be beneficial in the context of a desired abscopal effect, because radiotherapy could amplify the immunogenic stimulus provided by these neoantigens. Such a link remains purely hypothetical at this time and deserves additional study. Furthermore, the induction of an abscopal effect may require optimal timing and dosing of radiation. Relevant studies have almost exclusively been performed in preclinical models, but this evidence suggests that concurrent radiotherapy and immunotherapy is more beneficial than sequential administration. 20 The ideal dosing regimen to achieve an abscopal effect also remains undetermined, but one study that used mouse models of breast and colon cancer showed that a fractionated strategy was superior to a single large dose. 21 Although these approaches certainly were effective in our patient, forthcoming data from prospective trials are awaited. 22 Our report adds to the overall evidence in support of an abscopal effect, and it raises the possibility that immunotherapy can be periodically boosted by radiotherapy; however, additional studies are needed to validate such an approach. Given the infrequency of abscopal effects, the identification of predictive biomarkers should also be a future objective so that these treatments can be used in a safe and effective manner.
